EPIDEMIOLOGICAL STUDY OF HUMAN BRUCELLOSIS IN THE KINGDOM OF SAUDI ARABIA; PRE- AND DURING COVID-19 PANDEMIC
Human Brucellosis in the Kingdom of Saudi Arabia
DOI:
https://doi.org/10.26873/SVR-1645-2022Keywords:
brucellosis, incidence, epidemiology, Saudi Arabia, COVID-19 pandemicAbstract
Brucellosis is one of the most reported zoonotic diseases that affects human health with subsequent economic losses. Brucellosis is an endemic disease in countries in many regions such as the Kingdom of Saudi Arabia (KSA) in the Middle East. On 30 Jan 2020, the Director-General of the World Health Organisation (WHO) declared the novel coronavirus outbreak (later named COVID-19) a public health emergency of international concern. In KSA, on 2 March 2020, the first case of COVID-19 was confirmed. To contain the disease outbreak, partial and full suspension of public activities/curfew started in March and April. In this study, characterization of brucellosis in KSA from 2013-2019 (pre-pandemic), the year 2020 (pandemic control interventions’” year), and the year 2021is presented. Incidence data were obtained from the Ministry of Health’s (MoH) records for laboratory-confirmed cases. Extracted incidence data were analysed according to the nationality of the patients (Saudi and non-Saudi), gender (male and female), age, health regions (20 throughout KSA), and months. From 2013-2019, there were 28073 (mean; 4010) cases of human brucellosis reported. In 2020 and 2021, there were 2372 and 2400 cases of brucellosis reported, respectively. The decrease in 2021, which continued after easing PCI restrictions, is worth noting. This represents a decrease of 59.15% of reported cases compared to incidence means for the period 2013-2019. Compared to other studies, misdiagnosis, delayed diagnosis, patients not seeking medical examination, and dedicating much of the health sector for COVID-19 patients are likely reasons for brucellosis reporting reduction. However, and due to lack of additional necessary data, it is not possible currently to conclude that PCI have (or have not) influenced reducing brucellosis in KSA. Additionally, and in comparison, to reported regional and global incidence rates of the disease, reported rates from 2013-2019 in KSA are likely to be underreported.
References
● 1. Kirk MD, Pires SM, Black RE, Caipo M, Crump JA, Devleesschauwer B, Döpfer D, Fazil A, Fischer–Walker CL, Hald T, Hall AJ. World Health Organization estimates of the global and regional disease burden of 22 foodborne bacterial, protozoal, and viral diseases, 2010: a data synthesis. PLoS medicine. 2015 Dec 3;12(12):e1001921.
● 2. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. The Lancet infectious diseases. 2006 Feb 1;6(2):91–9.
● 3. Rubach MP, Halliday JE, Cleaveland S, Crump JA. Brucellosis in low–income and middle–income countries. Current opinion in infectious diseases. 2013 Oct;26(5):404.
● 4. Olsen SC, Palmer MV. Advancement of knowledge of Brucella over the past 50 years. Veterinary pathology. 2014 Nov;51(6):1076–89.
● 5. Poester FP, Samartino LE, Santos RL. Pathogenesis and pathobiology of brucellosis in livestock. Rev Sci Tech. 2013 Apr 1;32(1):105–5.
● 6. Corbel MJ. Brucellosis in humans and animals. World Health Organization; 2006.
● 7. Galinska EM, Zagórski J. Brucellosis in humans–etiology, diagnostics, clinical forms. Annals of agricultural and environmental medicine. 2013;20(2).
● 8. McDermott J, Grace D, Zinsstag J. Economics of brucellosis impact and control in low–income countries. Revue scientifique et technique (International Office of Epizootics). 2013 Apr 1;32(1):249–61.
● 9. Franc KA, Krecek RC, Häsler BN, Arenas–Gamboa AM. Brucellosis remains a neglected disease in the developing world: a call for interdisciplinary action. BMC public health. 2018 Dec;18(1):1–9.
● 10. WHO. COVID19 overview. 2022. Available at; https://covid19.who.int/ (accessed November 18, 2022).
● 11. Kenny G, Mallon PW. COVID19–clinical presentation and therapeutic considerations. Biochemical and biophysical research communications. 2021 Jan 29;538:125–31.
● 12. Khan A, Alsofayan Y, Alahmari A, Alowais J, Algwizani A, Alserehi H, Assiri A, Jokhdar H. COVID–19 in Saudi Arabia: the national health response. Eastern Mediterranean Health Journal. 2021;27(11):1114–24.
● 13. General Authority for Statistics Population, provinces, and food import. 2018. Retrieved from https://www.stats.gov.sa/
● 14. Ministry of Health. Yearly Statistical Books. 2022. Retrieved from https://www.moh.gov.sa/Ministry/Statistics/book/Pages/default.aspx
● 15. Al Mofleh IA, Al Aska AI, Al Sekait MA, Al Balla SR, Al Nasser AN. Brucellosis in Saudi Arabia: Epidemiology in the central region. Annals of Saudi medicine. 1996 May;16(3):349–52.
● 16. Al Sekait MA. Seroepidemiological survey of brucellosis antibodies in Saudi Arabia. Annals of Saudi medicine. 1999 May;19(3):219–22.
● 17. Elbeltagy KE. An epidemiological profile of brucellosis in Tabuk Province, Saudi Arabia. EMHJ–Eastern Mediterranean Health Journal, 7 (4–5), 791–798, 2001.
● 18. Fallatah SM, Oduloju AJ, Al–Dusari SN, Fakunle YM. Human brucellosis in Northern Saudi Arabia. Saudi medical journal. 2005 Oct 1;26(10):1562–6.
● 19. Alballa SR. Epidemiology of human brucellosis in southern Saudi Arabia. The Journal of tropical medicine and hygiene. 1995 Jun 1;98(3):185–9.
● 20. Malik GM. A clinical study of brucellosis in adults in the Asir region of southern Saudi Arabia. The American journal of tropical medicine and hygiene. 1997 Apr 1;56(4):375–7.
● 21. Asaad AM, Alqahtani JM. Serological and molecular diagnosis of human brucellosis in Najran, Southwestern Saudi Arabia. Journal of infection and public health. 2012 Apr 1;5(2):189–94.
● 22. Rahamathulla MP. Seroprevalence of human brucellosis in Wadi Al Dawaser region of Saudi Arabia. Pakistan Journal of Medical Sciences. 2019 Jan;35(1):129.
● 23. Memish Z. Brucellosis control in Saudi Arabia: prospects and challenges. Journal of chemotherapy. 2001 Apr 1;13(sup1):11–7.
● 24. Ma C, Guo X, Wang L, Li W, Liu S, Lin F, Xu W. The impact of the COVID–19 pandemic on the incidence and mortality of zoonotic diseases in China. BMJ global health. 2022 Jan 1;7(1):e007109.
● 25. Tsagkaris C, Laskaratou ED, Alexiou A. COVID–19 can delay the timely diagnosis of musculoskeletal brucellosis: A summary of evidence and recommendations for healthcare practitioners and health bodies. Ethics, Medicine, and Public Health. 2022 Feb;20:100743.
● 26. Arrighi HM. Brucellosis surveillance in Saudi Arabia’s eastern province. Annals of Saudi Medicine. 1986;6(4):S5–10.
● 27. Hafez, S. M. The impact of uncontrolled animal importation and marketing on the prevalence of brucellosis in Saudi Arabia. Annals of Saudi Medicine. 1986; 6(4), S15–S18.
● 28. Radwan AI, Asmar JA, Frerichs WM, Bekairi SI, Al–Mukayel AA. Incidence of brucellosis in domestic livestock in Saudi Arabia. Tropical animal health and production. 1983 Sep;15(3):139–43.
● 29. Qais H, SR S. Current experience with brucellosis at Security Forces Hospital, Riyadh.1986; 6(4), S11–S14.
● 30. Bilal NE, Jamjoom GA, Bobo RA, Aly OF, El–Nashar NM. A study of the knowledge, attitude and practice (KAP) of a Saudi Arabian community towards the problem of brucellosis. The Journal of the Egyptian Public Health Association. 1991 Jan 1;66(1–2):227–38.
● 31. Cooper CW. Risk factors in transmission of brucellosis from animals to humans in Saudi Arabia. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1992 Mar 1;86(2):206–9.
● 32. Refai M. Incidence and control of brucellosis in the Near East region. Veterinary microbiology. 2002 Dec 20;90(1–4):81–110.
● 33. Dean AS, Crump L, Greter H, Schelling E, Zinsstag J. Global burden of human brucellosis: a systematic review of disease frequency. PLoS neglected tropical diseases. 2012 Oct 25;6(10):e1865.
● 34. Al–Eissa YA. Brucellosis in Saudi Arabia: past, present and future. Annals of Saudi medicine. 1999 Sep;19(5):403–5.
● 35. Kiel FW, Khan MY. Brucellosis in Saudi Arabia. Social Science & Medicine. 1989 Jan 1;29(8):999–1001.
● 36. Food and Agriculture Organisation of the United Nations, World Organization of Animal Health, World Health Organization, editor. Brucellosis in humans and animals. Geneva, Switzerland: World Health Organization. 2006. Available at: http://www.who.int/csr/resources/publications/Brucellosis.pdf
● 37. Aloufi AD, Memish ZA, Assiri AM, McNabb SJ. Trends of reported human cases of brucellosis, Kingdom of Saudi Arabia, 2004–2012. Journal of Epidemiology and Global Health. 2016 Mar 1;6(1):11–8.
● 38. Shaqra QM. Epidemiological aspects of brucellosis in Jordan. European journal of epidemiology. 2000 Jun;16(6):581–4.
● 39. Al–Haddad AM, Al–Madhagi AK, Talab AA, Al–Shamahy HA. The prevalence of human brucellosis in three selected areas in Al–Dala’a governorate, Yemen. Faculty Sci Bull. 2013;25:61–71.
● 40. Lulu AR, Araj GF, Khateeb MI, Mustafa MY, Yusuf AR, Fenech FF. Human brucellosis in Kuwait: a prospective study of 400 cases. QJM: An International Journal of Medicine. 1988 Jan 1;66(1):39–54.
● 41. Dimitrov TS, Panigrahi D, Emara M, Awni F, Passadilla R. Seroepidemiological and microbiological study of brucellosis in Kuwait. Medical Principles and Practice. 2004;13(4):215–9.
● 42. Zhai J, Peng R, Wang Y, Lu Y, Yi H, Liu J, Lu J, Chen Z. Factors Associated With Diagnostic Delays in Human Brucellosis in Tongliao City, Inner Mongolia Autonomous Region, China. Frontiers in Public Health. 2021:1418.
● 43. Crump JA, Youssef FG, Luby SP, Wasfy MO, Rangel JM, Taalat M, Oun SA, Mahoney FJ. Estimating the incidence of typhoid fever and other febrile illnesses in developing countries. Emerging infectious diseases. 2003 May;9(5):539.
● 44. Majowicz SE, Musto J, Scallan E, Angulo FJ, Kirk M, O'Brien SJ, Jones TF, Fazil A, Hoekstra RM, International Collaboration on Enteric Disease “Burden of Illness” Studies. The global burden of nontyphoidal Salmonella gastroenteritis. Clinical infectious diseases. 2010 Mar 15;50(6):882–9.
● 45. Murray CJ, Lopez AD. Measuring the global burden of disease. New England Journal of Medicine. 2013 Aug 1;369(5):448–57.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Abdullah F. Alsayeqh
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
